Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Redoy Ranjan, Gie Ken-Dror, Ida Martinelli, Elvira Grandone, Sini Hiltunen, Erik Lindgren, Maurizio Margaglione, Veronique Le Cam Duchez, Aude Triquenot Bagan, Marialuisa Zedde, Nicola Giannini, Ynte M Ruigrok, Bradford B Worrall, Jennifer J Majersik, Jukka Putaala, Elena Haapaniemi, Susanna M Zuurbier, Matthijs C Brouwer, Serena M Passamonti, Maria Abbattista, Paolo Bucciarelli, Robin Lemmens, Emanuela Pappalardo, Paolo Costa, Marina Colombi, Diana Aguiar de Sousa, Sofia Rodrigues, Patrícia Canhão, Aleksander Tkach, Rosa Santacroce, Giovanni Favuzzi, Antonio Arauz, Donatella Colaizzo, Kostas Spengos, Amanda Hodge, Reina Ditta, Alessandro Pezzini, Jonathan M Coutinho, Vincent Thijs, Katarina Jood, Turgut Tatlisumak, José M Ferro, Pankaj Sharma
BACKGROUND AND PURPOSE: Coma is an independent predictor of poor clinical outcomes in cerebral venous thrombosis (CVT). We aimed to describe the association of age, sex, and radiological characteristics of adult coma patients with CVT. METHODS: We used data from the international, multicentre prospective observational BEAST (Biorepository to Establish the Aetiology of Sinovenous Thrombosis) study. Only positively associated variables with coma with <10% missing data in univariate analysis were considered for the multivariate logistic regression model...
April 22, 2024: European Journal of Neurology
#2
Meithem Ali, Nonyelum Obiechina, Kay Teck Ling, Angela Nandi, Bhaskar Mukherjee
Cerebral venous sinus thrombosis (CVST) is a rare cause of strokes and is most common in younger patients particularly those less than 50 years of age. It is more common in females than in males and is known to be associated with pregnancy, puerperium, oral contraception, congenital and acquired thrombophilia, and malignancy. Less commonly, it has been shown to be associated with infections and more recently has been found to be associated with COVID-19 infection with thrombocytopenia and the COVID-19 vaccine AstraZeneca...
March 2024: Curēus
#3
JOURNAL ARTICLE
C Weimar, J Beyer-Westendorf, F O Bohmann, G Hahn, S Halimeh, S Holzhauer, C Kalka, M Knoflach, H-C Koennecke, F Masuhr, M-L Mono, U Nowak-Göttl, E Scherret, M Schlamann, B Linnemann
Over the last years, new evidence has accumulated on multiple aspects of diagnosis and management of cerebral venous and dural sinus thrombosis (CVT) including identification of new risk factors, studies on interventional treatment as well as treatment with direct oral anticoagulants. Based on the GRADE questions of the European Stroke Organization guideline on this topic, the new German guideline on CVT is a consensus between expert representatives of Austria, Germany and Switzerland. New recommendations include:• CVT occurring in the first weeks after SARS-CoV-2 vaccination with vector vaccines may be associated with severe thrombocytopenia, indicating the presence of a prothrombotic immunogenic cause (Vaccine-induced immune thrombotic thrombocytopenia; VITT)...
April 19, 2024: Neurological research and practice
#4
JOURNAL ARTICLE
Multicenter registry study of cerebral venous thrombosis in china (RETAIN-CH): Rationale and design.
Hetao Bian, Xia Wang, Lan Liu, Feng Yan, Shan Lu, Wen Hui, Chen Zhou, Jiangang Duan, Min Li, Jian Chen, Ran Meng, Lei Cao, Longde Wang, Xunming Ji
BACKGROUND AND RATIONALE: Cerebral venous thrombosis (CVT) is a rare cerebrovascular disorder that mainly affects young and middle-aged adults. Epidemiological data on the incidence, risk factors, diagnosis, treatment, and prognosis of CVT are lacking in China. In addition, there is a lack of evidence from large, multicenter, real-world studies on the efficacy and safety of endovascular. AIM: To understand the incidence, diagnosis and treatment status of CVT in China and to estimate the effectiveness and safety of endovascular treatment in the real-world...
April 2024: Brain and Behavior
#5
JOURNAL ARTICLE
Piers Klein, Liqi Shu, Erik Lindgren, Maria A de Winter, James E Siegler, Alexis N Simpkins, Satareh Salehi Omran, Mirjam R Heldner, Adam de Havenon, Mohamad Abdalkader, Sami Al Kasab, Christoph Stretz, Teddy Y Wu, Duncan Wilson, Syed Daniyal Asad, Eyad Almallouhi, Jennifer Frontera, Lindsey Kuohn, Aaron Rothstein, Ekaterina Bakradze, Nils Henninger, Adeel S Zubair, Richa Sharma, Deborah Kerrigan, Yasmin Aziz, Eva A Mistry, Mayte Sanchez van Kammen, Turgut Tatlisumak, Katarzyna Krzywicka, Diana Aguiar de Sousa, Katarina Jood, Thalia S Field, Shadi Yaghi, Jonathan M Coutinho, Thanh N Nguyen
OBJECTIVES: Prognostication for cerebral venous thrombosis (CVT) remains difficult. We sought to validate the SI2 NCAL2 C score in an international cohort. MATERIALS AND METHODS: The SI2 NCAL2 C score was originally developed to predict poor outcome (modified Rankin Scale (mRS) 3-6) at 6 months, and mortality at 30 days and 1 year using data from the International CVT Consortium. The SI2 NCAL2 C score uses 9 variables: the absence of any female-sex-specific risk factors, intracerebral hemorrhage, central nervous system infection, focal neurological deficits, coma, age, lower level of hemoglobin, higher level of glucose, and cancer...
April 11, 2024: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
#6
JOURNAL ARTICLE
Joao Meira Goncalves, Vasco Carvalho, António Cerejo, Patricia Polónia, Elisabete Monteiro
The natural history and epidemiological aspects of traumatic cerebral venous thrombosis (CVT) are not fully understood. Due to the concomitant occurrence with intracranial hemorrhages, guidelines for medical treatment have been highly controversial. In this study, our objective was to carry out an analysis description of the population and to conduct a literature review. A prospectively gathered radiology registry data of patients hospitalized at the tertiary hospital of Centro Hospitalar Universitário do São João, Porto, Portugal, between 2016 and 2021 was carried out...
March 2024: Curēus
#7
REVIEW
Aadarsh Netha, Saad Mazhar, Aima Azhar, Abdul Moeez, Aakash Choradia, Ali Mohtashim, Usama Anees, Umer Ejaz, Muhammad Uzair Tariq, Sayed Jawad
BACKGROUND: Cerebral venous thromboembolism (CVT) poses a significant risk of venous infarction and haemorrhage, which can lead to neurological deficits and, in severe cases, even death. The optimal treatment regimen for patients with CVT remains unclear. METHODS: MEDLINE, Embase, Google Scholar, Web of Science (WoS), and Cochrane Central databases were searched for randomized controlled trials (RCTs) and observational studies assessing the efficacy and safety of rivaroxaban in patients with CVT...
April 2024: Annals of Medicine and Surgery
#8
JOURNAL ARTICLE
Adrian Scutelnic, Anita van de Munckhof, Angel T Miraclin, Sanjith Aaron, Sajid Hameed, Mohammad Wasay, Oxana Grosu, Katarzyna Krzywicka, Mayte Sánchez van Kammen, Erik Lindgren, Tiago Moreira, Roberto Acampora, Alberto Negro, Theodoros Karapanayiotides, Shadi Yaghi, Anna Revert, Elisa Cuadrado Godia, Sebastian Garcia-Madrona, Paolino La Spina, Francesco Grillo, Fabrizio Giammello, Thanh N Nguyen, Mohamad Abdalkader, Alina Buture, Maria Sofia Cotelli, Nicolas Raposo, Georgios Tsivgoulis, Paolo Candelaresi, Antonio Ciacciarelli, Joshua Mbroh, Tatiana Batenkova, Pasquale Scoppettuolo, Marialuisa Zedde, Rosario Pascarella, Kateryna Antonenko, Espen S Kristoffersen, Johanna A Kremer Hovinga, Katarina Jood, Diana Aguiar de Sousa, Sven Poli, Turgut Tatlisumak, Jukka Putaala, Jonathan M Coutinho, José M Ferro, Marcel Arnold, Mirjam R Heldner
INTRODUCTION: Previous reports and meta-analyses derived from small case series reported a mortality rate of up to 40% in patients with coronavirus disease 2019 associated cerebral venous thrombosis (COVID-CVT). We assessed the clinical characteristics and outcomes in an international cohort of patients with COVID-CVT. PATIENTS AND METHODS: This was a registry study of consecutive COVID-CVT patients diagnosed between March 2020 and March 2023. Data collected by the International Cerebral Venous Thrombosis Consortium from patients with CVT diagnosed between 2017 and 2018 served as a comparison...
April 4, 2024: European Stroke Journal
#9
JOURNAL ARTICLE
Sanjit Aaron, Jorge M Ferreira, Jonathan M Coutinho, Patrícia Canhão, Adriana B Conforto, Antonio Arauz, Marta Carvalho, Jaime Masjuan, Vijay K Sharma, Jukka Putaala, Maarten Uyttenboogaart, David J Werring, Rodrigo Bazan, Sandeep Mohindra, Jochen Weber, Bert A Coert, Prabhu Kirubakaran, Mayte Sanchez van Kammen, Pankaj Singh, Diana Aguiar de Sousa, José M Ferro
BACKGROUND: Decompressive neurosurgery is recommended for patients with cerebral venous thrombosis (CVT) who have large parenchymal lesions and impending brain herniation. This recommendation is based on limited evidence. We report long-term outcomes of patients with CVT treated by decompressive neurosurgery in an international cohort. METHODS: DECOMPRESS2 (Decompressive Surgery for Patients With Cerebral Venous Thrombosis, Part 2) was a prospective, international cohort study...
April 4, 2024: Stroke; a Journal of Cerebral Circulation
#10
JOURNAL ARTICLE
João André Sousa, Maider Iza Achutegui, Jesus Juega-Mariño, Manuel Requena, Sara Bernardo-Castro, Marc Rodrigo-Gisbert, Federica Rizzo, Marta Olivé, Álvaro Garcia-Tornel, Ana Carolina Chaves, Noelia Rodriguez-Villatoro, Marian Muchada, Jorge Pagola, David Rodriguez-Luna, Marta Rubiera, Ana Inês Martins, Fernando Silva, Ricardo Veiga, Cesar Nunes, Egídio Machado, Francesco Diana, Marta de Dios, David Hernández, Marc Ribo, Carlos Molina, João Sargento-Freitas, Alejandro Tomasello
INTRODUCTION: After several uncontrolled studies and one randomized clinical trial, there is still uncertainty regarding the role of endovascular treatment (EVT) in cerebral venous thrombosis (CVT). This study aims to describe and assess different acute management strategies in the treatment of CVT. METHODS: We performed a retrospective analysis of an international two-center registry of CVT patients admitted since 2019. Good outcome was defined as a return to baseline modified Rankin scale at three months...
March 31, 2024: Interventional Neuroradiology
#11
JOURNAL ARTICLE
Ameya Patwardhan, Manisha Gupta, Mariamma Philip, Anush Rangarajan, Tarachand Joshi, Suvarna Alladi, Girish B Kulkarni, Subasree Ramakrishnan
BACKGROUND: Deep cerebral venous thrombosis (DCVT) can have long-term functional and cognitive sequelae. Although literature exists on cognitive impairment after arterial stroke, cognitive sequelae after cerebral venous thrombosis (CVT) are much less studied. METHODS: Clinical records of 29 patients diagnosed with DCVT were reviewed. The Modified Telephonic Interview for Cognitive Status (TICS-M) was adapted and validated in the regional language (Kannada) and applied to 18 patients with DCVT, at a mean follow-up duration of 5...
2024: Annals of Indian Academy of Neurology
#12
JOURNAL ARTICLE
Jonathan M Coutinho, Anita van de Munckhof, Diana Aguiar de Sousa, Sven Poli, Sanjith Aaron, Antonio Arauz-Góngora, Adriana Conforto, Katarzyna Krzywicka, Sini Hiltunen, Erik Lindgren, Mayte Sanchez van Kammen, Liqi Shu, Tamam Bakchoul, Rosalie Belder, Rene van den Berg, Elisheva Boumans, Suzanne Cannegieter, Vanessa Cano-Nigenda, Thalia Shoshana Field, Isabel Fragata, Mirjam R Heldner, María Hernández-Pérez, Frederikus A Klok, Ronen R Leker, Lia Lucas Neto, Jeremy Molad, Thanh N Nguyen, Dirk-Jan Saaltink, Gustavo Saposnik, Pankaj Sharma, Jan Stam, Vincent Thijs, Michiel van der Vaart, David Werring, Diana Wong Ramos, Shadi Yaghi, Nilufer Yesilot, Turgut Tatlisumak, Jukka Putaala, Katarina Jood, Marcel Arnold, Jose M Ferro
BACKGROUND: Due to the rarity of cerebral venous thrombosis (CVT), performing high-quality scientific research in this field is challenging. Providing answers to unresolved research questions will improve prevention, diagnosis, and treatment, and ultimately translate to a better outcome of patients with CVT. We present an international research agenda, in which the most important research questions in the field of CVT are prioritized. AIMS: This research agenda has three distinct goals: (1) To provide inspiration and focus to research on CVT for the coming years; (2) To reinforce international collaboration; and (3) To facilitate the acquisition of research funding...
March 17, 2024: International Journal of Stroke: Official Journal of the International Stroke Society
#13
JOURNAL ARTICLE
Lingjia Xu, Guoping Fu
RATIONALE: Cerebral venous thrombosis (CVT) is a relatively uncommon but fatal disease. It can be caused by a variety of hereditary or acquired thrombotic diseases. Initial presentation with intracranial hemorrhage (ICH) in CVT is rare but can further complicate the therapeutic measures and prognosis. Cases of CVT presented with ICH in patients with alcoholic liver disease (ALD) have not been described in the literature, and it might be related with hemostatic abnormalities in ALD patients...
March 8, 2024: Medicine (Baltimore)
#14
REVIEW
Clara Cohen, Stéphanie Lenck, Atika Talbi, Héloïse Ifergan, Kévin Premat, Grégoire Boulouis, Kévin Janot, Anne-Laure Boch, Christophe Magni, Denis Herbreteau, Nader Sourour, Eimad Shotar, Valère Barrot, Frédéric Clarençon
OBJECTIVE: The pathogenesis of intracranial dural arteriovenous fistulas (icDAVFs) is controversial. Cerebral vein thrombosis (CVT) and venous hypertension are recognized predisposing factors. This study aimed to evaluate the incidence of association between icDAVF and CVT and describe baseline aggressiveness and clinical outcomes for icDAVFs associated with CVT. The authors also performed a literature review of studies reporting icDAVF associated with CVT. METHODS: Two hundred sixty-three consecutive patients in two university hospitals with confirmed icDAVFs were included...
March 2024: Neurosurgical Focus
#15
JOURNAL ARTICLE
Ariel N Carrion, Teresa A Allison, Sophie Samuel
In managing cerebral venous sinus thrombosis (CVT), the standard approach has been administering parenteral anticoagulation for at least five days, despite limited supporting evidence. This study aimed to determine the optimal duration of parenteral anticoagulation for CVT patients and its potential impact on their functional outcomes upon discharge. This retrospective observational cohort study was conducted across multiple healthcare centers and included adult CVT patients who received varying durations of parenteral anticoagulation: less than 5 days (n = 25) or 5 days or more (n = 16)...
February 28, 2024: Journal of Thrombosis and Thrombolysis
#16
JOURNAL ARTICLE
Piers Klein, Liqi Shu, Muhammad M Qureshi, Mohamad Abdalkader, Thalia S Field, James E Siegler, Lily W Zhou, Karan Patel, Sami Al Kasab, Adam de Havenon, Shadi Yaghi, Adnan I Qureshi, Thanh N Nguyen
OBJECTIVES: We sought to provide updated incidence and trend data for cerebral venous thrombosis (CVT) in the United States from 2016-2020, examine the impact of the COVID-19 pandemic on CVT, and identify predictors of in-hospital mortality. MATERIALS AND METHODS: Validated ICD-10 codes were used to identify discharges with CVT in the National Inpatient Sample (NIS). Sample weights were applied to generate nationally representative estimates, and census data were used to compute incidence rates...
February 24, 2024: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
#17
JOURNAL ARTICLE
Minh Van Le, Tam Thai Thanh Tran, Loc Phu Huynh, Tho Kieu Anh Pham, Thi Van Vo, Hung Huynh Vinh Ly
BACKGROUND: Cerebral venous thrombosis (CVT) is a challenging condition with potential long-term consequences, but it is also a treatable disorder that offers the possibility of complete recovery. This study was conducted to comprehensively investigate the clinical features, brain imaging findings, and treatment outcomes of patients diagnosed with cerebral venous thrombosis. MATERIALS AND METHODS: Conducted as a cross-sectional descriptive study, patients diagnosed with cerebral venous thrombosis were enrolled at Can Tho Central General Hospital between January 2021 and June 2022...
2024: International Journal of General Medicine
#18
JOURNAL ARTICLE
Amal A AlSerehi, Basmah M Al Mufarrih, Amani Abu-Shaheen, Ahmed Saleh, Mohammed AlSheef
BACKGROUND AND AIMS: Since pregnancy is considered one of the major risk factors of cerebral venous thrombosis (CVT), the safety of pregnancy in women of childbearing age and a previous history of CVT, is concerning in terms of prevention, family planning, and management. This study aims to estimate the prevalence of pregnancies among women of childbearing age with previous CVT, evaluate the pregnancy-associated risk of CVT recurrence, and explore the maternal and fetal outcomes among CVT women in comparison with pregnant women without a history of CVT...
February 2024: Health Science Reports
#19
JOURNAL ARTICLE
Hongrui Ma, Yaqin Gu, Tingting Bian, Haiqing Song, Zhi Liu, Xunming Ji, Jiangang Duan
BACKGROUND: The efficacy and safety of dabigatran etexilate for Chinese patients with cerebral venous thrombosis (CVT) has not been well established. METHODS: CHOICE-CVT was an exploratory, single-center, randomized, open-label study in the National Center for Neurological Disorders involving Chinese patients with CVT aged 18 to 80 years who were randomly assigned (1:1) to either dabigatran etexilate or warfarin. Oral anticoagulants were initiated after 10-15 days of LMWH...
February 26, 2024: International Journal of Stroke: Official Journal of the International Stroke Society
#20
JOURNAL ARTICLE
Yasaman Pirahanchi, Kristin Salottolo, Christian Burrell, Xu Tang, David Bar-Or, Russell Bartt
OBJECTIVE: There are no studies to date that examine the association between anti-factor-Xa (AFXa)-based heparin monitoring and clinical outcomes in the setting of cerebral venous thrombosis (CVT). METHODS: This pilot study included adults aged ≥18 admitted with CVT between 1 January 2018 and 1 January 2021, who were treated with unfractionated heparin (UFH) and were monitored via AFXa-based nomogram within 24 h of arrival. Comparisons were made between patients with AFXa levels within the target therapeutic range (0...
2024: Frontiers in Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
